Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials

Harmony Biosciences Holdings, Inc. -0.18% Pre

Harmony Biosciences Holdings, Inc.

HRMY

27.96

27.45

-0.18%

-1.82% Pre

Harmony Biosciences Holdings Inc. has announced a collaboration with Beacon Biosignals to incorporate quantitative electroencephalography (EEG) measurements into two Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The partnership aims to enhance the assessment of excessive daytime sleepiness by combining traditional patient-reported outcomes with objective EEG data. Beacon's FDA-cleared Waveband EEG headband and AI-driven algorithms will be used to collect at-home brain data, providing more precise and objective clinical endpoints for hypersomnia conditions. This initiative is expected to improve the evaluation of treatment benefits and advance precision medicine in sleep disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9602792) on December 16, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.